Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avadomide Combinations in DLBCL and FL
NCT02031419Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Dec 2013
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of avadomide in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (4 arms), sponsored by Celgene Corporation. Primary endpoint: Safety and Tolerability. Started Dec 2013; status: terminated.
02
Drugs
avadomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02031419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02031419.